Innate Pharma to Present Promising Phase 2 Results for Lung Cancer Treatment at AACR 2026
Innate Pharma is set to present interim results from its MATISSE Phase 2 study at the AACR Annual Meeting 2026. The study evaluates IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy for resectable non-small cell lung cancer (NSCLC). The interim analysis of 40 patients showed promising results, with higher pathological complete response rates compared to the benchmark set by durvalumab plus chemotherapy alone. The study continues to recruit patients with tumors expressing PD-L1≥1%, aiming to enhance anti-tumor immune responses and improve clinical outcomes in early-stage lung cancer. 
